Alan P Venook

Summary

Affiliation: University of California
Country: USA

Publications

  1. pmc Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581
    Alan P Venook
    University of California San Francisco Cancer Center, 1600 Divisadero Street, San Francisco, CA 94115, USA
    J Clin Oncol 31:1775-81. 2013
  2. ncbi request reprint Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565
    A P Venook
    University of California San Francisco, San Francisco, CA, USA
    J Clin Oncol 18:2780-7. 2000
  3. ncbi request reprint Cancer and Leukemia Group B/Southwest Oncology Group trial 80405: a phase III trial of chemotherapy and biologics for patients with untreated advanced colorectal adenocarcinoma
    Alan P Venook
    Cancer and Leukemia Group B, Department of Clinical Medicine, University of California San Francisco, 600 Divisadero Box 1770, San Francisco, CA 94115, USA
    Clin Colorectal Cancer 5:292-4. 2005
  4. ncbi request reprint Revisiting the Cancer and Leukemia Group B/Southwest Oncology Group 80405 Trial: a phase III trial of chemotherapy and biologic agents for patients with untreated advanced colorectal adenocarcinoma
    Alan P Venook
    Cancer and Leukemia Group B, University of California, San Francisco, CA 94115, USA
    Clin Colorectal Cancer 6:536-8. 2007
  5. ncbi request reprint Critical evaluation of current treatments in metastatic colorectal cancer
    Alan Venook
    Division of Medical Oncology, Clinical Research Office, University of California Cancer Center, Box 1705, 1600 Divisadero, San Francisco, California 94115 1705, USA
    Oncologist 10:250-61. 2005
  6. ncbi request reprint Emerging therapies for metastatic colorectal cancer: focus on EGFR and VEGF inhibition
    Alan P Venook
    Department of Clinical Medicine, University of California, San Francisco, San Francisco, California 94115, USA
    J Natl Compr Canc Netw 2:S74-84. 2004
  7. ncbi request reprint Key research issues in the management of hepatocellular carcinoma
    Alan P Venook
    University of California, San Francisco, UCSF Mt Zion Cancer Center, 1600 Divisadero, Box 1705, San Francisco, CA 94115, USA
    Cancer Chemother Pharmacol 54:S87-90. 2004
  8. doi request reprint The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective
    Alan P Venook
    Division of Medical Oncology, University of California San Francisco, San Francisco, California 94115, USA
    Oncologist 15:5-13. 2010
  9. ncbi request reprint A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863
    A P Venook
    UCSF Cancer Center, University of California at San Francisco, San Francisco, CA 94115 1705, USA
    Ann Oncol 14:1783-90. 2003
  10. ncbi request reprint Therapeutic approaches to metastasis confined to the liver
    A P Venook
    University of California, San Francisco School of Medicine, Box 0324, San Francisco, CA 94143 0324, USA
    Curr Oncol Rep 3:109-15. 2001

Detail Information

Publications63

  1. pmc Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581
    Alan P Venook
    University of California San Francisco Cancer Center, 1600 Divisadero Street, San Francisco, CA 94115, USA
    J Clin Oncol 31:1775-81. 2013
    ....
  2. ncbi request reprint Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565
    A P Venook
    University of California San Francisco, San Francisco, CA, USA
    J Clin Oncol 18:2780-7. 2000
    ..To ascertain if hepatic or renal dysfunction leads to increased toxicity at a given dose of gemcitabine and to characterize the pharmacokinetics of gemcitabine and its major metabolite in patients with such dysfunction...
  3. ncbi request reprint Cancer and Leukemia Group B/Southwest Oncology Group trial 80405: a phase III trial of chemotherapy and biologics for patients with untreated advanced colorectal adenocarcinoma
    Alan P Venook
    Cancer and Leukemia Group B, Department of Clinical Medicine, University of California San Francisco, 600 Divisadero Box 1770, San Francisco, CA 94115, USA
    Clin Colorectal Cancer 5:292-4. 2005
  4. ncbi request reprint Revisiting the Cancer and Leukemia Group B/Southwest Oncology Group 80405 Trial: a phase III trial of chemotherapy and biologic agents for patients with untreated advanced colorectal adenocarcinoma
    Alan P Venook
    Cancer and Leukemia Group B, University of California, San Francisco, CA 94115, USA
    Clin Colorectal Cancer 6:536-8. 2007
  5. ncbi request reprint Critical evaluation of current treatments in metastatic colorectal cancer
    Alan Venook
    Division of Medical Oncology, Clinical Research Office, University of California Cancer Center, Box 1705, 1600 Divisadero, San Francisco, California 94115 1705, USA
    Oncologist 10:250-61. 2005
    ..This review discusses the role of the individual agents in the treatment of mCRC and identifies the most effective regimens...
  6. ncbi request reprint Emerging therapies for metastatic colorectal cancer: focus on EGFR and VEGF inhibition
    Alan P Venook
    Department of Clinical Medicine, University of California, San Francisco, San Francisco, California 94115, USA
    J Natl Compr Canc Netw 2:S74-84. 2004
    ..Treatment with either does not appear to exacerbate chemotherapy-related toxicity...
  7. ncbi request reprint Key research issues in the management of hepatocellular carcinoma
    Alan P Venook
    University of California, San Francisco, UCSF Mt Zion Cancer Center, 1600 Divisadero, Box 1705, San Francisco, CA 94115, USA
    Cancer Chemother Pharmacol 54:S87-90. 2004
    ..The immense unique challenges of this disease make it imperative for investigators to identify the most promising agents for HCC. At the same time, all patients with HCC should, if possible, be treated on well-designed clinical trials...
  8. doi request reprint The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective
    Alan P Venook
    Division of Medical Oncology, University of California San Francisco, San Francisco, California 94115, USA
    Oncologist 15:5-13. 2010
    ..A new and global approach to the study of HCC epidemiology is required if HCC disease prevention and treatment strategies are to be adequately directed and supported in coming years...
  9. ncbi request reprint A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863
    A P Venook
    UCSF Cancer Center, University of California at San Francisco, San Francisco, CA 94115 1705, USA
    Ann Oncol 14:1783-90. 2003
    ....
  10. ncbi request reprint Therapeutic approaches to metastasis confined to the liver
    A P Venook
    University of California, San Francisco School of Medicine, Box 0324, San Francisco, CA 94143 0324, USA
    Curr Oncol Rep 3:109-15. 2001
    ..This review identifies unique patient subgroups and novel treatment approaches that may be indicated in patients with liver metastases...
  11. doi request reprint A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer
    Andrew H Ko
    University of California at San Francisco Helen Diller Family Comprehensive Cancer Center, 1600 Divisadero Street, 4th Floor, Box 1705, San Francisco, CA 94115, USA
    Cancer Chemother Pharmacol 66:1051-7. 2010
    ..Based on potential for additive or synergistic activity by concurrent inhibition of VEGF and EGFR, we conducted a phase II study evaluating the combination of bevacizumab plus erlotinib in this patient population...
  12. ncbi request reprint A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer
    Andrew H Ko
    Division of Hematology Oncology, University of California at San Francisco, San Francisco, CA 94115, USA
    Int J Radiat Oncol Biol Phys 68:809-16. 2007
    ..We conducted a Phase II nonrandomized trial to evaluate sequential chemotherapy followed by chemoradiation in this patient population...
  13. doi request reprint A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable?
    Andrew H Ko
    University of California at San Francisco Comprehensive Cancer Center, 1600 Divisadero Street, 4th Floor, Box 1705, San Francisco, CA, 94115, USA
    Invest New Drugs 26:463-71. 2008
    ..The objectives of this study were to determine safety and efficacy in chemotherapy-naive patients with metastatic pancreatic cancer receiving bevacizumab in combination with fixed-dose rate (FDR) gemcitabine and low-dose cisplatin...
  14. ncbi request reprint Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas
    Andrew H Ko
    Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA
    Am J Clin Oncol 35:411-7. 2012
    ....
  15. doi request reprint Lymph node sampling rates and predictors of nodal metastasis in pancreatic neuroendocrine tumor resections: the UCSF experience with 149 patients
    Justin R Parekh
    Division of Surgical Oncology, Department of Surgery, University of California, San Francisco, San Francisco, CA, USA
    Pancreas 41:840-4. 2012
    ..We sought to identify clinicopathological factors that predict nodal disease...
  16. doi request reprint Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy
    Derrick Wong
    University of California at San Francisco Comprehensive Cancer Center, San Francisco, CA, USA
    Pancreas 37:269-74. 2008
    ..Serum carbohydrate antigen 19-9 (CA19-9) has never been compared to radiographic objective response as a surrogate for clinical outcomes in patients receiving chemotherapy for metastatic pancreatic cancer...
  17. doi request reprint Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study
    Andrew H Ko
    University of California at San Francisco Comprehensive Cancer Center, San Francisco, California 94115, USA
    Cancer Invest 26:47-52. 2008
    ..We, therefore, evaluated this regimen in patients with gemcitabine-refractory disease...
  18. ncbi request reprint Induction therapy in patients with metastatic colorectal cancer
    Alan P Venook
    University of California San Francisco Cancer Center, 94115, USA
    Semin Oncol 30:25-9. 2003
  19. doi request reprint Adjuvant treatment of colon cancer: what is next?
    Katherine Van Loon
    Division of Hematology Oncology, Department of Medicine, University of California San Francisco, San Francisco, California 94115, USA
    Curr Opin Oncol 23:403-9. 2011
    ..In addition, we examine how results of these trials have shaped our knowledge and outline directions for future research...
  20. ncbi request reprint Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas
    Andrew H Ko
    University of California at San Francisco Comprehensive Cancer Center, San Francisco, CA 94115, USA
    J Clin Oncol 24:379-85. 2006
    ..The objectives of this study were to determine safety and efficacy in patients with metastatic pancreatic cancer treated with FDR gemcitabine in combination with low-dose cisplatin...
  21. doi request reprint Identification of unknown primary tumors in patients with neuroendocrine liver metastases
    Sam C Wang
    Department of Surgery, Division of Surgical Oncology, University of California San Francisco, 1600 Divisadero Street, San Francisco, CA 94143 1932, USA
    Arch Surg 145:276-80. 2010
    ..Despite preoperative evaluation, the primary tumor location may remain unknown...
  22. ncbi request reprint Systemic and regional nonsurgical therapy--what is the optimal strategy for metastatic neuroendocrine cancer?
    Eric K Nakakura
    Department of Surgery, Division of Surgical Oncology, University of California, UCSF Comprehensive Cancer Center, 1600 Divisadero Street, A 724, San Francisco, CA 94143 1932, USA
    Surg Oncol Clin N Am 16:639-51, x. 2007
    ..A proposed treatment algorithm is provided with the aim of providing clinicians with a useful framework for managing these challenging patients. Finally, the rationale for promising investigational therapies is described...
  23. ncbi request reprint Targeted therapy in colorectal cancer
    Supriya Rajpal
    University of California, San Francisco, Division of Hematology Oncology, 505 Parnassus Avenue, Box 1270, San Francisco, CA 94143 1270, USA
    Clin Adv Hematol Oncol 4:124-32. 2006
    ..Further advances in the treatment of CRC are expected through continued scientific investigation and well-designed clinical trials...
  24. ncbi request reprint Colorectal metastases confined to the liver: a unique opportunity?
    Alan P Venook
    Department of Clinical Medicine, University of California San Francisco Comprehensive Cancer Center, San Francisco, CA 94115 1705, USA
    Semin Oncol 30:34-9. 2003
    ....
  25. ncbi request reprint Frequency of hepatic contour abnormalities and signs of portal hypertension at CT in patients receiving chemotherapy for breast cancer metastatic to the liver
    Aliya Qayyum
    Department of Radiology, University of California San Francisco, San Francisco, CA 94143 0628, USA
    Clin Imaging 31:6-10. 2007
    ..This study aimed to determine the frequency of hepatic contour abnormalities and signs of portal hypertension at serial CT in patients receiving chemotherapy for breast cancer metastatic to the liver...
  26. ncbi request reprint Epidermal growth factor receptor-targeted treatment for advanced colorectal carcinoma
    Alan P Venook
    Department of Medicine, University of California San Francisco, San Francisco, California 94115, USA
    Cancer 103:2435-46. 2005
    ..Numerous molecules targeting the epidermal growth factor receptor have been investigated as therapeutic agents and appear to herald a shift in the treatment paradigm for colorectal carcinoma...
  27. doi request reprint Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207
    J E Rosenberg
    Division of Hematology and Oncology, University of California, San Francisco Cancer Center, San Francisco, CA 94115, USA
    Ann Oncol 19:946-50. 2008
    ..Response rates to second-line chemotherapy for advanced UC are low and response duration is short. Bortezomib is a proteasome inhibitor with preclinical activity against UC...
  28. ncbi request reprint Drug development in advanced colorectal cancer: challenges and opportunities
    Robin Kelley
    University of California, San Francisco, 1600 Divisadero Street, Box 1705, San Francisco, CA 94115, USA
    Curr Oncol Rep 11:175-85. 2009
    ..It concludes with a selection of promising agents and pathways under investigation in ACC...
  29. pmc Prognostic and predictive markers in stage II colon cancer: is there a role for gene expression profiling?
    Robin K Kelley
    University of California, San Francisco, The Helen Diller Family Comprehensive Cancer Center, San Francisco, CA 94115, USA
    Clin Colorectal Cancer 10:73-80. 2011
    ..Current evidence for both of these assays is described below, concluding with a discussion of potential future directions for gene expression profiling in colon cancer risk stratification and treatment decision making...
  30. ncbi request reprint Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer
    J Randolph Hecht
    University of California School of Medicine, Los Angeles, CA, USA
    Cancer 110:980-8. 2007
    ..The safety and efficacy of the fully human antibody panitumumab was evaluated in patients with metastatic colorectal cancer refractory to available therapies...
  31. ncbi request reprint The impact of pre-operative loco-regional therapy on outcome after liver transplantation for hepatocellular carcinoma
    Francis Y Yao
    Department of Medicine, University of California, San Francisco, CA, USA
    Am J Transplant 5:795-804. 2005
    ....
  32. doi request reprint Lactic acidosis and colon cancer: oncologic emergency?
    Anne M Espinoza
    University of California, San Francisco, USA
    Clin Colorectal Cancer 10:194-7. 2011
    ..It is important to report this case of a rare but serious complication of malignancy in order to increase recognition and understanding of this presentation...
  33. pmc Comparison of dietary and lifestyle habits among stage III and metastatic colorectal cancer patients: findings from CALGB 89803 and CALGB 80405
    Katherine Van Loon
    Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94115, USA
    Clin Colorectal Cancer 12:95-102. 2013
    ..We describe the prevalence of a wide-range of health-related dietary patterns and lifestyle behaviors among colorectal cancer patients with stage III and metastatic disease and report notable similarities in these 2 cohorts...
  34. ncbi request reprint Hepatocellular carcinoma: epidemic and treatment
    Jill Allen
    Division of Gastrointestinal Oncology, University of California at San Francisco School of Medicine, UCSF Medical Center, 1600 Divisadero, Box 1705, San Francisco, CA 94115 1610, USA
    Curr Oncol Rep 6:177-83. 2004
    ..Prevention through vaccination remains a mainstay of this epidemic. New staging systems that incorporate important information about tumor characteristics and liver disease improve our ability to prognosticate and treat these patients...
  35. ncbi request reprint Counterpoint: Adjuvant therapy in stage II colon cancer: pain not justified by the gain
    Katherine Van Loon
    Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, 1600 Divisadero Street, San Francisco, CA 94115, USA
    J Natl Compr Canc Netw 10:1379-86. 2012
    ..Given what is now known, the viewpoint is that the aggregate data do not support adjuvant therapy for patients with normal-risk stage II colon cancer...
  36. ncbi request reprint Predictive biomarkers in advance of a companion drug: ahead of their time?
    Robin K Kelley
    Department of Medicine, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California 94143, USA
    J Natl Compr Canc Netw 10:303-9. 2012
    ..A great need exists for comprehensive and dynamic practice guidelines for all types of biomarker testing according to tumor type...
  37. pmc Biomarker use in colorectal cancer therapy
    Robin K Kelley
    University of California, San Francisco, CA, USA
    J Natl Compr Canc Netw 9:1293-302. 2011
    ..A selection of biomarkers undergoing validation for future clinical application is presented, and the dynamic and challenging interface between biomarkers in research and clinical practice is discussed...
  38. ncbi request reprint Fractional genomic alteration detected by array-based comparative genomic hybridization independently predicts survival after hepatic resection for metastatic colorectal cancer
    Kshama R Mehta
    Comprehensive Cancer Center, Department of Surgery, University of California San Francisco, 2340 Sutter Street, San Francisco, CA 94143, USA
    Clin Cancer Res 11:1791-7. 2005
    ..Identification of molecular markers that predict patients at highest risk for recurrence may help to target further therapy...
  39. ncbi request reprint Hepatocellular carcinoma: regional therapy with a magnetic targeted carrier bound to doxorubicin in a dual MR imaging/ conventional angiography suite--initial experience with four patients
    Mark W Wilson
    Departments of Radiology and Medicine, University of California, San Francisco, 505 Parnassus Avenue, Room M 361, San Francisco, CA 94143, USA
    Radiology 230:287-93. 2004
    ..64 to 0.91. The fraction of affected normal liver volume ranged from 0.07 to 0.30. The dual MR imaging/conventional angiography system shows promise for directing magnetically targeted tumor therapies...
  40. pmc Personalized medicine and oncology practice guidelines: a case study of contemporary biomarkers in colorectal cancer
    Robin K Kelley
    Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, USA
    J Natl Compr Canc Netw 9:13-25. 2011
    ..Potential implications of this conclusion and future directions for research are discussed...
  41. doi request reprint Hepatocellular carcinoma: Ablate and wait versus rapid transplantation
    John P Roberts
    Division of Transplantation, University of California San Francisco, San Francisco, CA 94143 0780, USA
    Liver Transpl 16:925-9. 2010
    ....
  42. doi request reprint Novel therapeutics in hepatocellular carcinoma
    Robin K Kelley
    From the University of California, San Francisco, San Francisco, CA
    Am Soc Clin Oncol Educ Book 2013:137-42. 2013
    ..Collectively, these and other new strategies are needed to make progress in identifying active novel therapeutics for patients with HCC...
  43. ncbi request reprint Adjuvant and neoadjuvant therapy for esophageal cancer: a critical reappraisal
    Brendan C Visser
    Department of Surgery, University of California, 533 Parnassus Avenue, Room U 122, San Francisco, CA 94143 7088, USA
    Surg Oncol 12:1-7. 2003
    ..Future investigation must focus on the development of new biologic or chemotherapeutic agents, and the identification of biologic markers that might predict response to chemoradiation...
  44. ncbi request reprint Defining the role of hepatic arterial infusion chemotherapy in metastatic colorectal cancer
    Jonathan Whisenant
    University of California, San Francisco, USA
    Oncology (Williston Park) 18:762-8; discussion 769-73. 2004
    ..Moreover, in light of improved response rates and overall survival with newer more active chemotherapeutic and novel agents, the absolute role of HAI chemotherapy remains undefined...
  45. ncbi request reprint Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides
    Brian Kavanagh
    Department of Medicine, Division of Hematology Oncology, University of California, San Francisco, CA 94143, USA
    J Immunother 30:762-72. 2007
    ....
  46. ncbi request reprint Regional therapy of liver metastases
    Jonathan Whisenant
    UCSF Mt Zion Cancer Center, Medical Oncology, Fourth Floor, Box 1705, 1600 Divisadero, San Francisco, CA 94115, USA
    Curr Treat Options Oncol 5:427-37. 2004
    ..This review identifies unique patient subgroups that may benefit from regional therapy of liver metastases, and considers different treatment options and when these different options may be indicated...
  47. ncbi request reprint Rectal cancer clinical practice guidelines in oncology
    Paul F Engstrom
    Fox Chase Cancer Center, Philadelphia, PA, USA
    J Natl Compr Canc Netw 3:492-508. 2005
  48. ncbi request reprint Chemotherapy and regional therapy of hepatic colorectal metastases: expert consensus statement
    David L Bartlett
    Division of Surgical Oncology, University of Pittsburgh, Pennsylvania, USA
    Ann Surg Oncol 13:1284-92. 2006
  49. doi request reprint Hepatocellular carcinoma: the role of the North American GI Steering Committee Hepatobiliary Task Force and the advent of effective drug therapy
    BERT H O'NEIL
    University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599, USA
    Oncologist 12:1425-32. 2007
    ..This article briefly discusses the management of earlier stage HCC, then focuses on newer agents with promise, particularly sorafenib, a drug that appears to be the new standard of care for advanced disease...
  50. ncbi request reprint Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors
    Matthew H Kulke
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 24:3555-61. 2006
    ..We therefore performed a multicenter phase II study of rhEndostatin in patients with carcinoid or pancreatic neuroendocrine tumors...
  51. ncbi request reprint The cancer and leukemia group B pharmacology and experimental therapeutics committee: a historical perspective
    Mark J Ratain
    University of Chicago, Chicago, Illinois, USA
    Clin Cancer Res 12:3612s-6s. 2006
    ..It is anticipated that the results of the current studies will contribute significantly to the goal of individualizing cancer treatment...
  52. ncbi request reprint Colon cancer clinical practice guidelines in oncology
    Paul F Engstrom
    Fox Chase Cancer Center, Philadelphia, PA, USA
    J Natl Compr Canc Netw 3:468-91. 2005
  53. ncbi request reprint Cetuximab in the treatment of colorectal cancer
    Richard M Goldberg
    Division of Hematology Oncology, University of North Carolina, Chapell Hill, NC, USA
    Clin Adv Hematol Oncol 2:1-10; quiz 11-12. 2004
  54. ncbi request reprint An alternative therapy for patients with hepatic impairment?
    Su Pin Choo
    Onkologie 30:474-5. 2007
  55. ncbi request reprint Colon cancer
    Paul F Engstrom
    Fox Chase Cancer Center, USA
    J Natl Compr Canc Netw 5:884-925. 2007
  56. ncbi request reprint A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: cancer and leukemia group B study 89903
    Mitchell C Posner
    University of Chicago, 5841 S Maryland Avenue MC5031, Chicago 60637, IL, USA
    Ann Surg Oncol 15:158-64. 2008
    ....
  57. ncbi request reprint Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials
    David S Alberts
    The Arizona Cancer Center, Tucson, AZ, USA
    Semin Oncol 31:53-90. 2004
    ....
  58. ncbi request reprint Shedding old paradigms: developing viruses to treat cancer
    Emily K Bergsland
    J Clin Oncol 20:2220-2. 2002
  59. ncbi request reprint Anal canal cancer clinical practice guidelines in oncology
    Paul F Engstrom
    Fox Chase Cancer Center, Philadelphia, PA, USA
    J Natl Compr Canc Netw 3:510-5. 2005
  60. ncbi request reprint Rectal cancer
    Paul F Engstrom
    Fox Chase Cancer Center, USA
    J Natl Compr Canc Netw 5:940-81. 2007
  61. ncbi request reprint Hepatobiliary cancers. Clinical practice guidelines in oncology
    Al B Benson
    Robert H Luri Comprehensive Cancer Center of Northwestern University
    J Natl Compr Canc Netw 4:728-50. 2006
  62. ncbi request reprint Testing the water before diving off the cutting edge
    Alan P Venook
    Ann Surg Oncol 10:332-3. 2003
  63. ncbi request reprint Clinical utility of AFP-L3% measurement in North American patients with HCV-related cirrhosis
    Richard K Sterling
    Virginia Commonwealth University Health Systems, Richmond, Virginia, USA
    Am J Gastroenterol 102:2196-205. 2007
    ..The aim of this prospective study was to compare the clinical utility of AFP-L3% with that of total AFP in North American patients...